Keyword Connections

•  Erin Gribben

Resources

• No matching connections

Communities

• The Vanderbilt Antibody and Protein Resource

Publications

• Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.
  Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA
  (2008) N Engl J Med 358: 1109-17
• Beyond exon 2--the developing story of RAS mutations in colorectal cancer.
  Berlin J
  (2013) N Engl J Med 369: 1059-60
• Chemotherapy and immunotherapy in metastatic colorectal cancer.
  Pohlmann PR, Mernaugh RL, Goff LW
  (2009) N Engl J Med 360: 2134; author reply 2135-6
• New drugs for rheumatoid arthritis.
  Olsen NJ, Stein CM
  (2004) N Engl J Med 350: 2167-79
• Treatment of Ménétrier's disease with a monoclonal antibody against the epidermal growth factor receptor.
  Burdick JS, Chung E, Tanner G, Sun M, Paciga JE, Cheng JQ, Washington K, Goldenring JR, Coffey RJ
  (2000) N Engl J Med 343: 1697-701
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
  Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M
  (2012) N Engl J Med 366: 2443-54
• ERBB2 inhibition and heart failure.
  Cote GM, Sawyer DB, Chabner BA
  (2012) N Engl J Med 367: 2150-3
• ERBB2 inhibition and heart failure.
  Cote GM, Sawyer DB, Chabner BA
  (2013) N Engl J Med 368: 876
• Improved survival with ipilimumab in patients with metastatic melanoma.
  Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ
  (2010) N Engl J Med 363: 711-23
• Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
  Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, Hicks M, Puzanov I, Alexander MR, Bloomer TL, Becker JR, Slosky DA, Phillips EJ, Pilkinton MA, Craig-Owens L, Kola N, Plautz G, Reshef DS, Deutsch JS, Deering RP, Olenchock BA, Lichtman AH, Roden DM, Seidman CE, Koralnik IJ, Seidman JG, Hoffman RD, Taube JM, Diaz LA, Anders RA, Sosman JA, Moslehi JJ
  (2016) N Engl J Med 375: 1749-1755
• Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.
  Sapparapu G, Fernandez E, Kose N, Bin Cao , Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE
  (2016) Nature 540: 443-447
• Intracellular transport of class II MHC molecules directed by invariant chain.
  Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, Quaranta V, Peterson PA
  (1990) Nature 348: 600-5
• Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
  Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R
  (2012) Nature 483: 100-3
• The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.
  Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B
  (2012) Nature 486: 537-40
• Proof of principle for epitope-focused vaccine design.
  Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE, Johnson PR, Schief WR
  (2014) Nature 507: 201-6
• Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors.
  Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE
  (2008) Nature 455: 532-6
• Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection.
  Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE
  (2016) Cell 164: 392-405
• Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.
  Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS
  (2015) Cell 163: 1095-1107
• Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections.
  Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE
  (2016) Cell 167: 684-694.e9
• Mechanism of human antibody-mediated neutralization of Marburg virus.
  Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE
  (2015) Cell 160: 893-903
• Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires.
  Tian M, Cheng C, Chen X, Duan H, Cheng HL, Dao M, Sheng Z, Kimble M, Wang L, Lin S, Schmidt SD, Du Z, Joyce MG, Chen Y, DeKosky BJ, Chen Y, Normandin E, Cantor E, Chen RE, Doria-Rose NA, Zhang Y, Shi W, Kong WP, Choe M, Henry AR, Laboune F, Georgiev IS, Huang PY, Jain S, McGuire AT, Georgeson E, Menis S, Douek DC, Schief WR, Stamatatos L, Kwong PD, Shapiro L, Haynes BF, Mascola JR, Alt FW
  (2016) Cell 166: 1471-1484.e18
• Structural basis for Marburg virus neutralization by a cross-reactive human antibody.
  Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO
  (2015) Cell 160: 904-12
• DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers.
  Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE, Lok SM
  (2015) Science 349: 88-91
• A monoclonal antibody to the alpha subunit of Gk blocks muscarinic activation of atrial K+ channels.
  Yatani A, Hamm H, Codina J, Mazzoni MR, Birnbaumer L, Brown AM
  (1988) Science 241: 828-31
• A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.
  Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Aman MJ, Dye JM, Lai JR, Chandran K
  (2016) Science 354: 350-354
• Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit.
  Hamm HE, Deretic D, Arendt A, Hargrave PA, Koenig B, Hofmann KP
  (1988) Science 241: 832-5
• Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.
  Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS
  (2012) Lancet Oncol 13: 459-65
• Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
  Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG
  (2013) Lancet Oncol 14: 371-82
• EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
  Arteaga CL
  (2006) Cancer Cell 9: 421-3
• HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
  Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL
  (2006) Cancer Cell 10: 25-38
• The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151.
  Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP
  (2008) Cancer Cell 13: 221-34
• Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
  Arteaga CL, Baselga J
  (2004) Cancer Cell 5: 525-31
• ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
  Arteaga CL, Engelman JA
  (2014) Cancer Cell 25: 282-303